Target intelligence / Profile preview

Nuclear factor kappa B subunit 1 mRNA 3′ untranslated region (NFKB1 mRNA 3′UTR) (NFKB1 3′UTR)

Target
NFKB1 3′UTR
Molecular classification
RNA, Untranslated region (UTR)
01

Overview

The NF-κB1 mRNA 3′ untranslated region (3′UTR) is a critical regulatory segment of the messenger RNA encoding the p105 precursor of the NF-κB p50 subunit. This region serves as a hub for post-transcriptional control, containing multiple binding sites for microRNAs (miRNAs) and RNA-binding proteins (RBPs) that dictate mRNA stability and translation efficiency. For instance, miR-9 and miR-506 directly bind to the 3′UTR to suppress NF-κB1 expression, acting as tumor suppressors in various cancers such as ovarian and lung cancer. Conversely, the RBP RIG-I can bind to specific motifs within the 3′UTR to promote translation by recruiting ribosomal proteins, thereby enhancing NF-κB signaling. Dysregulation of this region, through mechanisms like alternative polyadenylation (3′UTR shortening) or altered miRNA expression, is linked to chronic inflammation, autoimmune disorders, and oncogenesis. Therapeutic strategies targeting the NF-κB1 3′UTR include miRNA mimics to downregulate the pathway and antisense oligonucleotides (ASOs) designed to modulate its regulatory interactions or stability.

Other names
NFKB1 3′UTRp105 mRNA 3′UTRp50 mRNA 3′UTRNuclear factor kappa B subunit 1 3′ untranslated region
02

Mechanism of action

RNA interference (RNAi) mediated by miRNA mimics to induce mRNA degradation or translational repression; Steric hindrance of regulatory protein binding (e.g., RIG-I) by antisense oligonucleotides; Modulation of alternative polyadenylation (APA) to control mRNA stability and protein output.

03

Biological functions

Post-transcriptional regulationmRNA stabilityTranslation controlmiRNA bindingAlternative polyadenylation
04

Disease associations

Cancer (e.g., Ovarian, Lung, Neuroblastoma, Glioblastoma)Inflammation (e.g., Rheumatoid arthritis, Ulcerative colitis)Autoimmune diseaseInfection (e.g., HCoV-OC43 viral pathogenesis)
05

Safety considerations

Off-target effects of RNA-based therapeuticsPotential for systemic inflammatory response (cytokine storm)Unintended suppression of anti-inflammatory p50 homodimer functionsDelivery challenges to specific tissues (e.g., blood-brain barrier for CNS cancers)
06

Interacting drugs

miR-9 mimics (experimental)

4 more in the full profile.

07

Biomarkers

NFKB1 mRNA levelsp50/p105 protein expressionmiR-9 expression levelsmiR-506 expression levels3′UTR length (Alternative Polyadenylation status)

Beyond the preview

Go deeper on Nuclear factor kappa B subunit 1 mRNA 3′ untranslated region (NFKB1 mRNA 3′UTR) (NFKB1 3′UTR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear factor kappa B subunit 1 mRNA 3′ untranslated region (NFKB1 mRNA 3′UTR) (NFKB1 3′UTR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call